---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-326309"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2026-07-30T20:49:21+00:00"
generated_at: "2026-07-30T20:50:04.413325+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ORIC Pharmaceuticals increases inducement equity plan share reserve by 1.1M shares to 3.35M total

## Summary
- Board approved Amended and Restated 2022 Inducement Plan, adding 1,100,000 shares of common stock.
- Total shares reserved under the plan now 3,350,000 for equity awards to new employees.
- Plan allows grants of nonstatutory stock options, RSUs, SARs, performance shares/units.
- Adopted without stockholder approval per Nasdaq Listing Rules as inducement grants.
- Plan terms are substantially similar to the company's 2020 Equity Incentive Plan.

## SEC filing metadata
- accession: 0001193125-26-326309
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2026-07-30T20:49:21+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000119312526326309/0001193125-26-326309-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000119312526326309/d169933d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-326309
- JSON: https://secwatch.observer/filing/0001193125-26-326309.json
- Plain text: https://secwatch.observer/filing/0001193125-26-326309.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.